Lawyers in Ontario, Canada have launched a class action lawsuit against health care products manufacturer Johnson & Johnson and other companies over injuries allegedly caused by transvaginal mesh products that were used to treat women with pelvic organ prolapse (POP) and stress urinary incontinence (SUI) – conditions that affect the proper positioning and function of one or more pelvic organs.
The Canadian Statement of Claim alleges that Johnson & Johnson failed to adequately warn patients and physicians of the magnitude of the risk posed by the transvaginal mesh devices in causing serious side effects compared to other methods of treating POP and SUI. Many women implanted with these surgical mesh products have experienced the devices eroding through the vaginal walls, perforation of the bladder and other organs, intense pain, infection, vaginal scarring, painful sexual intercourse, and numerous other injuries that can amount to a dismal quality of life filled with constant pain.
“We believe that through this lawsuit Johnson & Johnson will be required to explain to Canadians what it knew about the risks associated with using their transvaginal mesh products and when they first became aware of those risks,” said one lawyer working on the Canadian lawsuit. “In this case, as with all of these types of cases, we are concerned about whether Canadians were adequately warned of the risks associated with using the products in question.”
Hundreds of women in the United States also are taking Johnson & Johnson and other transvaginal mesh manufacturers to court, seeking damages for the devastating impact the mesh products allegedly have had on their lives.
In response to the growing number of lawsuits against transvaginal mesh makers, the U.S. Judicial Panel on Multidistrict Litigation chose to consolidate federal lawsuits into four multidistrict litigation (MDL) groups, all of which will be heard by Judge Joseph Goodwin in U.S. District Court for the Southern District of West Virginia.
The four MDLs involve lawsuits against C.R. Bard, Inc. / Sofradim Production (MDL 2187), Johnson & Johnson (MDL 2327), Boston Scientific Corp. (MDL 2326), and American Medical Systems Inc. (MDL 2325).